ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Eisai Co., Ltd.

Business Summary

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue695,621M6,397.94M
Gross Profit510,352M4,693.93M
Operating income138,679M1,275.49M
Income before tax128,063M1,177.85M
Net income121,767M1,119.94M
EBITDA172,379M1,585.44M
Diluted EPS424.793.90
Dividends Per Share1601.47
Total Assets1,062.14B9,838.72M
Total liabilities359,509M3,330.17M
Total equity678,127M6,281.57M
Operating cash flow102,782M945.33M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 547,922M 539,097M 600,054M 642,834M 695,621M
Gross Profit 339,839M 331,091M 386,599M 446,436M 510,352M
Operating income 42,779M 51,205M 75,595M 99,921M 138,679M
Income before tax 50,473M 57,668M 76,803M 89,454M 128,063M
Net income 54,933M 39,359M 51,845M 63,386M 121,767M
EBITDA 76,843M 77,689M 101,778M 126,762M 172,379M
Diluted EPS 191.76 137.41 180.97 221.11 424.79
Dividends Per Share 150 150 150 150 160
Total Assets 973,987M 1,030.76B 1,049.03B 1,071.52B 1,062.14B
Total liabilities 397,159M 428,172M 434,934M 419,539M 359,509M
Total equity 573,660M 584,630M 593,582M 628,120M 678,127M
Operating cash flow 95,617M 75,851M 149,649M 103,714M 102,782M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 4,562.81M 4,978.38M 5,414.06M 5,796.79M 6,397.94M
Gross Profit 2,830.00M 3,057.51M 3,488.14M 4,025.76M 4,693.93M
Operating income 356.24M 472.86M 682.06M 901.04M 1,275.49M
Income before tax 420.31M 532.54M 692.96M 806.65M 1,177.85M
Net income 457.45M 363.46M 467.77M 571.58M 1,119.94M
EBITDA 639.90M 717.43M 918.30M 1,143.08M 1,585.44M
Diluted EPS 1.59 1.26 1.63 1.99 3.90
Dividends Per Share 1.24 1.38 1.35 1.35 1.47
Total Assets 8,665.75M 9,250.32M 9,863.94M 9,680.80M 9,838.72M
Total liabilities 3,533.60M 3,842.51M 4,089.64M 3,790.38M 3,330.17M
Total equity 5,103.96M 5,246.61M 5,581.39M 5,674.84M 6,281.57M
Operating cash flow 796.24M 700.45M 1,350.22M 935.24M 945.33M

Valuation Measures

Mar 2020
PER18.66
ROA11.41%
ROE18.64%
Operating margin19.93%
Profit margin17.50%

Key executives

  • Chief Executive Officer & Representative Director: Haruo Naito
  • COO, Representative Executive Officer & Head-China: Yasushi Okada
  • Chief Financial Officer: Ryohei Yanagi
  • Chief Medical Officer & Managing Executive Officer: Edward Stewart Geary
  • Chief Medical & Chief Clinical Officer-Neurology: Lynn D. Kramer

Shareholders

  • Wellington Management Co. LLP (8.6%)
  • Nomura Asset Management Co., Ltd. (6.1%)
  • Government of Japan (5.0%)
  • Nippon Life Insurance Co. (4.1%)
  • Asset Management One Co., Ltd. (3.4%)
  • Eisai Co., Ltd. (3.3%)
  • Nikko Asset Management Co., Ltd. (2.8%)
  • Daiwa Asset Management Co. Ltd. (2.8%)
  • The Vanguard Group, Inc. (2.6%)
  • Resona Holdings, Inc. (2.2%)

Contact Details

  • Website:http://www.eisai.co.jp
  • Address: 4-6-10 Koishikawa, Bunkyo-Ku, Tokyo, 112-8088, Japan
  • Phone: +81.3.3817.3700

Related Companies

  • Eisai Europe Ltd.
  • Eisai LLC
  • Eisai Machinery China Co. Ltd.
  • Eisai Laboratorios S de RL de CV
  • Eisai GesmbH
  • Eisai Farmaceutica, Unipessoal Lda.
  • Eisai Clinical Research Singapore Pte Ltd.
  • Eisai Ltd. (Canada)
  • Eisai SA/NV
  • Eisai (Malaysia) Sdn. Bhd.
  • Eisai (Thailand) Marketing Co. Ltd.
  • Eisai AB
  • Eisai Pharma AG
  • Eisai (Singapore) Pte Ltd.
  • Eisai Co. Ltd. /Misato Factory/
  • Eisai Board Incentive Plan
  • Eisai Corporate Pension Fund
  • Eisai Pension Fund
  • Eisai China, Inc.
  • H3 Biomedicine, Inc.
  • Eisai R&D Management Co., Ltd.
  • Herusu Co., Ltd.
  • Gakuen Shoji Co., Ltd.
  • PT Eisai Indonesia
  • Eisai Taiwan, Inc.
  • Eisai (Hong Kong) Co. Ltd.
  • Eisai Australia Pty Ltd.
  • Eisai Pharmaceuticals India Pvt Ltd.
  • Eisai GmbH
  • Eisai SRL

Competitors

  • JW Holdings Corporation
  • Celltrion Pharm Inc.
  • Ipsen SA
  • Boryung Pharmaceutical Co., Ltd.
  • Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A
  • Denali Therapeutics Inc.
  • Arcutis Biotherapeutics Inc
  • Exelixis, Inc.
  • Blueprint Medicines Corp.
  • Oncternal Therapeutics, Inc.
  • Genkyotex SA
  • Vivoryon Therapeutics AG
  • ACADIA Pharmaceuticals Inc.
  • Spring Bank Pharmaceuticals, Inc.
  • Minerva Neurosciences Inc
  • Aptinyx Inc
  • Xenon Pharmaceuticals Inc.
  • Aprea Therapeutics, Inc.
  • Genfit SA
  • Aeolus Pharmaceuticals, Inc.
  • Mirati Therapeutics Inc.
  • Seagen, Inc.
  • Cortexyme, Inc.
  • InnoCare Pharma Limited
  • AC Immune SA
  • AVEO Pharmaceuticals, Inc.
  • Heron Therapeutics Inc
  • Phathom Pharmaceuticals, Inc.
  • Marinus Pharmaceuticals Inc
  • Onconova Therapeutics Inc.
Last Updated on 29 Oct, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more